Marshall Wace’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-929,019
| Closed | -$37.4M | – | 3142 |
|
|
2026
Q1 | $37.4M | Sell |
929,019
-61,829
| -6% | -$1.33M | 0.04% | 464 |
|
|
2025
Q4 | $24.9M | Buy |
990,848
+594,113
| +150% | +$13.9M | 0.02% | 557 |
|
|
2025
Q3 | $8.98M | Sell |
396,735
-2,308,102
| -85% | -$53.8M | 0.01% | 952 |
|
|
2025
Q2 | $46.8M | Buy |
2,704,837
+2,681,263
| +11,374% | +$49.6M | 0.05% | 309 |
|
|
2025
Q1 | $516K | Sell |
23,574
-61,921
| -72% | -$1.71M | ﹤0.01% | 2066 |
|
|
2024
Q4 | $2.73M | Buy |
85,495
+63,705
| +292% | +$1.92M | ﹤0.01% | 1321 |
|
|
2024
Q3 | $628K | Buy |
+21,790
| New | +$807K | ﹤0.01% | 1845 |
|
|
2024
Q2 | – | Sell |
-171,873
| Closed | -$10.1M | – | 2515 |
|
|
2024
Q1 | $10.1M | Sell |
171,873
-59,003
| -26% | -$3.76M | 0.02% | 747 |
|
|
2023
Q4 | $13.8M | Buy |
230,876
+61,582
| +36% | +$3.12M | 0.02% | 589 |
|
|
2023
Q3 | $6.44M | Sell |
169,294
-173,058
| -51% | -$7.6M | 0.01% | 784 |
|
|
2023
Q2 | $31.2M | Buy |
342,352
+249,906
| +270% | +$21.6M | 0.06% | 331 |
|
|
2023
Q1 | $6.1M | Sell |
92,446
-343,977
| -79% | -$19.8M | 0.01% | 897 |
|
|
2022
Q4 | $22.6M | Buy |
436,423
+99,696
| +30% | +$5.29M | 0.05% | 412 |
|
|
2022
Q3 | $23M | Sell |
336,727
-1,031,680
| -75% | -$61M | 0.05% | 412 |
|
|
2022
Q2 | $61.9M | Buy |
1,368,407
+453,244
| +50% | +$20.7M | 0.13% | 159 |
|
|
2022
Q1 | $46.5M | Buy |
+915,163
| New | +$40.4M | 0.09% | 249 |
|
|
2021
Q3 | – | Sell |
-10,375
| Closed | -$656K | – | 2995 |
|
|
2021
Q2 | $656K | Buy |
+10,375
| New | +$535K | ﹤0.01% | 2002 |
|
|
2019
Q1 | – | Sell |
-3,382
| Closed | -$45K | – | 1699 |
|
|
2018
Q4 | $45K | Buy |
+3,382
| New | +$51.9K | ﹤0.01% | 1455 |
|
Other funds holding APLS
Marshall Wace's APLS Position: Q2 2026 in Review
Marshall Wace sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 929,019 shares — an estimated $37.4M sold.
Marshall Wace first reported a position in APLS in Q4 2018 and held it in 18 quarters. The position peaked at $61.9M in Q2 2022. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Marshall Wace reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Marshall Wace sold 929,019 Apellis Pharmaceuticals shares in Q2 2026, an estimated $37.4M.
- Marshall Wace first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 18 quarters.
- Marshall Wace's Apellis Pharmaceuticals position peaked at $61.9M in Q2 2022.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.